Skip to main content
SpringerLink
Log in
Book cover

Pulmonary Manifestations of Rheumatic Disease pp 95–121Cite as

Pulmonary Manifestations of Sarcoidosis

  • Chapter
  • First Online:

  • 1415 Accesses

Abstract

Sarcoidosis is a multisystem disease that can cause a myriad of symptoms and clinical abnormalities. While sarcoidosis has been recognized in the modern medical literature for nearly 150 years, the cause of sarcoidosis is still unknown and the diagnosis remains one of exclusion. More than half of sarcoidosis patients have at least two organs involved, implying that diagnosis and management require a multidisciplinary approach. The prognosis of sarcoidosis is good for the majority of patients, but it is difficult to predict which ones will remit spontaneously at the outset of the disease. It does not appear that early treatment substantially influences the likelihood of spontaneous remission. Therefore, the indications for treatment fall broadly into the two categories of threats to organ function and significant impairment of the quality of life. A range of associated manifestations, such as pulmonary hypertension, mycetomas, upper airways involvement, and sleep apnea, may complicate the management of sarcoidosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. James DG. Descriptive definition and historic aspects of sarcoidosis. Clin Chest Med. 1997;18: 663–79.

    Article  CAS  PubMed  Google Scholar 

  2. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149–73.

    CAS  PubMed  Google Scholar 

  3. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev. 1983;5:124–56.

    CAS  PubMed  Google Scholar 

  4. Mayock RL, Bertrand P, Morrison CE, et al. Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med. 1963;35:67–89.

    Article  CAS  PubMed  Google Scholar 

  5. Edmondstone WM, Wilson AG. Sarcoidosis in Caucasians, Blacks and Asians in London. Br J Dis Chest. 1985;79:27–36.

    Article  CAS  PubMed  Google Scholar 

  6. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med. 1974;57:847–52.

    Article  CAS  PubMed  Google Scholar 

  7. Rybicki BA, Major M, Popovich Jr J, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–41.

    Article  CAS  PubMed  Google Scholar 

  8. Keller AZ. Hospital, age, racial, occupational, geographical, clinical and survivorship characteristics in the epidemiology of sarcoidosis. Am J Epidemiol. 1971;94:222–30.

    CAS  PubMed  Google Scholar 

  9. McNicol MW, Luce PJ. Sarcoidosis in a racially mixed community. J R Coll Physicians Lond. 1985;19:179–83.

    CAS  PubMed  Google Scholar 

  10. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–9.

    Article  CAS  PubMed  Google Scholar 

  11. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979–1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100: 423–7.

    Article  CAS  PubMed  Google Scholar 

  12. Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us? Clin Chest Med. 1997;18:681–94.

    Article  CAS  PubMed  Google Scholar 

  13. Reid JD. Sarcoidosis in coroner’s autopsies: a critical evaluation of diagnosis and prevalence from Cuyahoga County, Ohio. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15:44–51.

    CAS  PubMed  Google Scholar 

  14. Henke CE, Henke G, Elveback LR, et al. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123:840–5.

    CAS  PubMed  Google Scholar 

  15. Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. II. Course and prognosis. Sarcoidosis. 1990;7:113–8.

    CAS  PubMed  Google Scholar 

  16. Hillerdal G, Nou E, Osterman K, et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130:29–32.

    CAS  PubMed  Google Scholar 

  17. Cozier YC, Berman JS, Palmer JR, et al. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest. 2011;139: 144–50.

    Article  PubMed Central  PubMed  Google Scholar 

  18. James DG. Epidemiology of sarcoidosis. Sarcoidosis. 1992;9:79–87.

    CAS  PubMed  Google Scholar 

  19. Culver DA, Thomassen MJ, Kavuru MS. Pulmonary sarcoidosis: new genetic clues and ongoing treatment controversies. Cleve Clin J Med. 2004;71:88. 90, 92 passim.

    Article  PubMed  Google Scholar 

  20. Culver DA, Newman LS, Kavuru MS. Gene-environment interactions in sarcoidosis: challenge and opportunity. Clin Dermatol. 2007;25:267–75.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Newman KL, Newman LS. Occupational causes of sarcoidosis. Curr Opin Allergy Clin Immunol. 2012;12:145–50.

    Article  CAS  PubMed  Google Scholar 

  22. Gentry JT, Nitowsky HM, Michael Jr M. Studies on the epidemiology of sarcoidosis in the United States: the relationship to soil areas and to urban–rural residence. J Clin Invest. 1955;34:1839–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–30.

    Article  PubMed  Google Scholar 

  24. Rybicki BA, Amend KL, Maliarik MJ, et al. Photocopier exposure and risk of sarcoidosis in African-American sibs. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:49–55.

    PubMed  Google Scholar 

  25. Kajdasz DK, Lackland DT, Mohr LC, et al. A current assessment of rurally linked exposures as potential risk factors for sarcoidosis. Ann Epidemiol. 2001;11: 111–7.

    Article  CAS  PubMed  Google Scholar 

  26. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201:755–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Oswald-Richter KA, Culver DA, Hawkins C, et al. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun. 2009;77: 3740–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Chen ES, Wahlstrom J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181:8784–96.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Drake W, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30:201–11.

    PubMed Central  PubMed  Google Scholar 

  30. Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149:1040–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360–73.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Eishi Y. Etiologic link between sarcoidosis and Propionibacterium acnes. Respir Investig. 2013;51:56–68.

    Article  PubMed  Google Scholar 

  33. Oswald-Richter KA, Beachboard DC, Seeley EH, et al. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol. 2012;32:1129–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Culver DA. What is sarcoidosis? Respir Med. 2013;107:1285–6.

    Article  PubMed  Google Scholar 

  35. Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med. 2010;31:380–9.

    Article  PubMed  Google Scholar 

  36. Sverrild A, Backer V, Kyvik KO, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008;63:894–6.

    Article  CAS  PubMed  Google Scholar 

  37. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case–control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164:2085–91.

    Article  CAS  PubMed  Google Scholar 

  38. McGrath DS, Daniil Z, Foley P, et al. Epidemiology of familial sarcoidosis in the UK. Thorax. 2000;55:751–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73:720–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet. 2013;50:290–7.

    Article  CAS  PubMed  Google Scholar 

  41. Culver DA, Costabel U. EBUS-TBNA for the diagnosis of sarcoidosis: is it the only game in town? J Bronchology Interv Pulmonol. 2013;20:195–7.

    Article  PubMed  Google Scholar 

  42. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183:573–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Grunewald J, Eklund A. Sex-specific manifestations of Lofgren’s syndrome. Am J Respir Crit Care Med. 2007;175:40–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Highland KB, Retalis P, Coppage L, et al. Is there an anatomic explanation for chest pain in patients with pulmonary sarcoidosis? South Med J. 1997;90:911–4.

    Article  CAS  PubMed  Google Scholar 

  45. Judson MA, Thompson BW, Rabin DL, et al. The diagnostic pathway to sarcoidosis. Chest. 2003;123:406–12.

    Article  PubMed  Google Scholar 

  46. Sweiss NJ, Patterson K, Sawaqed R, et al. Rheumatologic manifestations of sarcoidosis. Semin Respir Crit Care Med. 2010;31:463–73.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Yanardag H, Caner M, Papila I, et al. Diagnostic value of peripheral lymph node biopsy in sarcoidosis: a report of 67 cases. Can Respir J. 2007;14:209–11.

    PubMed Central  PubMed  Google Scholar 

  48. Culver DA. Sarcoidosis. Immunol Allergy Clin North Am. 2012;32:487–511.

    Article  PubMed  Google Scholar 

  49. Fireman E, Haimsky E, Noiderfer M, et al. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:144–8.

    PubMed  Google Scholar 

  50. Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance—a review. J Clin Pathol. 1983;36:938–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Lieberman J, Nosal A, Schlessner A, et al. Serum angiotensin-converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis. 1979;120:329–35.

    CAS  PubMed  Google Scholar 

  52. Borowsky SA, Lieberman J, Strome S, et al. Elevation of serum angiotensin—converting enzyme level. Occurrence in alcoholic liver disease. Arch Intern Med. 1982;142:893–5.

    Article  CAS  PubMed  Google Scholar 

  53. Ainslie GM, Benatar SR. Serum angiotensin converting enzyme in sarcoidosis: sensitivity and specificity in diagnosis: correlations with disease activity, duration, extra-thoracic involvement, radiographic type and therapy. Q J Med. 1985;55:253–70.

    CAS  PubMed  Google Scholar 

  54. Biller H, Zissel G, Ruprecht B, et al. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;28:1085–90.

    Article  CAS  PubMed  Google Scholar 

  55. Bargagli E, Bennett D, Maggiorelli C, et al. Human chitotriosidase: a sensitive biomarker of sarcoidosis. J Clin Immunol. 2013;33:264–70.

    Article  CAS  PubMed  Google Scholar 

  56. Bargagli E, Bianchi N, Margollicci M, et al. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest. 2008;68:479–83.

    Article  CAS  PubMed  Google Scholar 

  57. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49:1510–7.

    Article  CAS  PubMed  Google Scholar 

  58. Studdy PR, Bird R, Neville E, et al. Biochemical findings in sarcoidosis. J Clin Pathol. 1980;33: 528–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Hedfors E, Holm G, Pettersson D. Lymphocyte subpopulations in sarcoidosis. Clin Exp Immunol. 1974;17:219–26.

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Winterbauer RH, Belic N, Moores KD. Clinical interpretation of bilateral hilar adenopathy. Ann Intern Med. 1973;78:65–71.

    Article  CAS  PubMed  Google Scholar 

  61. Reich JM, Brouns MC, O’Connor EA, et al. Mediastinoscopy in patients with presumptive stage I sarcoidosis: a risk/benefit, cost/benefit analysis. Chest. 1998;113:147–53.

    Article  CAS  PubMed  Google Scholar 

  62. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.

    Article  PubMed  Google Scholar 

  63. Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011;55:66–71.

    CAS  PubMed  Google Scholar 

  64. Teirstein AS, Judson MA, Baughman RP, et al. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:139–46.

    PubMed  Google Scholar 

  65. Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of conventional TBNA in sarcoidosis: a systematic review and meta-analysis. Respir Care. 2013;58(4):683–93.

    PubMed  Google Scholar 

  66. von Bartheld MB, Dekkers OM, Szlubowski A, et al. Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis: the GRANULOMA randomized clinical trial. JAMA. 2013;309:2457–64.

    Article  Google Scholar 

  67. Costabel U, Bonella F, Ohshimo S, et al. Diagnostic modalities in sarcoidosis: BAL, EBUS, and PET. Semin Respir Crit Care Med. 2010;31:404–8.

    Article  PubMed  Google Scholar 

  68. Trisolini R, Lazzari Agli L, Cancellieri A, et al. The value of flexible transbronchial needle aspiration in the diagnosis of stage I sarcoidosis. Chest. 2003;124:2126–30.

    Article  PubMed  Google Scholar 

  69. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 2001;120:109–14.

    Article  CAS  PubMed  Google Scholar 

  70. Bilaceroglu S, Perim K, Gunel O, et al. Combining transbronchial aspiration with endobronchial and transbronchial biopsy in sarcoidosis. Monaldi Arch Chest Dis. 1999;54:217–23.

    CAS  PubMed  Google Scholar 

  71. Plit M, Pearson R, Havryk A, et al. Diagnostic utility of endobronchial ultrasound-guided transbronchial needle aspiration compared with transbronchial and endobronchial biopsy for suspected sarcoidosis. Intern Med J. 2012;42:434–8.

    Article  CAS  PubMed  Google Scholar 

  72. Nagai S, Izumi T. Bronchoalveolar lavage. Still useful in diagnosing sarcoidosis? Clin Chest Med. 1997;18:787–97.

    Article  CAS  PubMed  Google Scholar 

  73. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185:1004–14.

    Article  PubMed  Google Scholar 

  74. Rosen Y, Vuletin JC, Pertschuk LP, et al. Sarcoidosis: from the pathologist’s vantage point. Pathol Annu. 1979;14(Pt 1):405–39.

    PubMed  Google Scholar 

  75. Ohara K, Okubo A, Kamata K, et al. Transbronchial lung biopsy in the diagnosis of suspected ocular sarcoidosis. Arch Ophthalmol. 1993;111:642–4.

    Article  CAS  PubMed  Google Scholar 

  76. Sartin JS, Walker RC. Granulomatous hepatitis: a retrospective review of 88 cases at the Mayo Clinic. Mayo Clin Proc. 1991;66:914–8.

    Article  CAS  PubMed  Google Scholar 

  77. Morimoto Y, Routes JM. Granulomatous disease in common variable immunodeficiency. Curr Allergy Asthma Rep. 2005;5:370–5.

    Article  CAS  PubMed  Google Scholar 

  78. Brincker H. Granulomatous lesions of unknown significance: the GLUS syndrome. In: James D, editor. Sarcoidosis and other granulomatous disorders. New York: Marcel Dekker; 1994. p. 69–76.

    Google Scholar 

  79. Judson MA. The diagnosis of sarcoidosis. Clin Chest Med. 2008;29:415–27. viii.

    Article  PubMed  Google Scholar 

  80. Rose CD, Martin TM, Wouters CH. Blau syndrome revisited. Curr Opin Rheumatol. 2011;23:411–8.

    Article  CAS  PubMed  Google Scholar 

  81. Wallaert B, Ramon P, Fournier EC, et al. Activated alveolar macrophage and lymphocyte alveolitis in extrathoracic sarcoidosis without radiological mediastinopulmonary involvement. Ann N Y Acad Sci. 1986;465:201–10.

    Article  CAS  PubMed  Google Scholar 

  82. Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2009;136(2):526–35.

    CAS  PubMed  Google Scholar 

  83. Bergin CJ, Bell DY, Coblentz CL, et al. Sarcoidosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests. Radiology. 1989;171:619–24.

    CAS  PubMed  Google Scholar 

  84. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J. 1961;5261:1165–72.

    Article  Google Scholar 

  85. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:90–8.

    CAS  PubMed  Google Scholar 

  86. Lynch III JP, Ma YL, Koss MN, et al. Pulmonary sarcoidosis. Semin Respir Crit Care Med. 2007;28:53–74.

    Article  PubMed  Google Scholar 

  87. Sharma OP, Johnson R. Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest. 1988;94:343–6.

    Article  CAS  PubMed  Google Scholar 

  88. Harrison BD, Shaylor JM, Stokes TC, et al. Airflow limitation in sarcoidosis—a study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med. 1991;85:59–64.

    Article  CAS  PubMed  Google Scholar 

  89. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest. 2001;120: 881–6.

    Article  CAS  PubMed  Google Scholar 

  90. Mihailovic-Vucinic V, Zugic V, Videnovic-Ivanov J. New observations on pulmonary function changes in sarcoidosis. Curr Opin Pulm Med. 2003;9:436–41.

    Article  PubMed  Google Scholar 

  91. Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med. 1997;18:755–85.

    Article  PubMed  Google Scholar 

  92. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38:628–34.

    Article  CAS  PubMed  Google Scholar 

  93. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax. 2005;60:32–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  94. Panselinas E, Halstead L, Schlosser RJ, et al. Clinical manifestations, radiographic findings, treatment options, and outcome in sarcoidosis patients with upper respiratory tract involvement. South Med J. 2010;103:870–5.

    Article  PubMed  Google Scholar 

  95. Aubart FC, Ouayoun M, Brauner M, et al. Sinonasal involvement in sarcoidosis: a case–control study of 20 patients. Medicine (Baltimore). 2006;85:365–71.

    Article  Google Scholar 

  96. McCaffrey TV, McDonald TJ. Sarcoidosis of the nose and paranasal sinuses. Laryngoscope. 1983;93: 1281–4.

    CAS  PubMed  Google Scholar 

  97. Yanardag H, Enoz M, Papila I, et al. Upper respiratory tract involvement of sarcoidosis in the Turkish population. Otolaryngol Head Neck Surg. 2006;134:848–51.

    Article  PubMed  Google Scholar 

  98. Carasso B. Sarcoidosis of the larynx causing airway obstruction. Chest. 1974;65:693–5.

    Article  CAS  PubMed  Google Scholar 

  99. Krespi YP, Mitrani M, Husain S, et al. Treatment of laryngeal sarcoidosis with intralesional steroid injection. Ann Otol Rhinol Laryngol. 1987;96:713–5.

    CAS  PubMed  Google Scholar 

  100. Marks SC, Goodman RS. Surgical management of nasal and sinus sarcoidosis. Otolaryngol Head Neck Surg. 1998;118:856–8.

    Article  CAS  PubMed  Google Scholar 

  101. Neville E, Mills RG, Jash DK, et al. Sarcoidosis of the upper respiratory tract and its association with lupus pernio. Thorax. 1976;31:660–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  102. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;52:525–33.

    CAS  PubMed  Google Scholar 

  103. Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J. 1993; 6:349–53.

    CAS  PubMed  Google Scholar 

  104. Chambellan A, Turbie P, Nunes H, et al. Endoluminal stenosis of proximal bronchi in sarcoidosis: bronchoscopy, function, and evolution. Chest. 2005;127: 472–81.

    Article  PubMed  Google Scholar 

  105. Udwadia ZF, Pilling JR, Jenkins PF, et al. Bronchoscopic and bronchographic findings in 12 patients with sarcoidosis and severe or progressive airways obstruction. Thorax. 1990;45:272–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  106. Davies CW, Tasker AD, Padley SP, et al. Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol. 2000;55: 217–21.

    Article  CAS  PubMed  Google Scholar 

  107. Lavergne F, Clerici C, Sadoun D, et al. Airway obstruction in bronchial sarcoidosis: outcome with treatment. Chest. 1999;116:1194–9.

    Article  CAS  PubMed  Google Scholar 

  108. Polychronopoulos VS, Prakash UB. Airway involvement in sarcoidosis. Chest. 2009;136:1371–80.

    Article  PubMed  Google Scholar 

  109. Battesti JP, Georges R, Basset F, et al. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax. 1978;33:76–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  110. Gluskowski J, Hawrylkiewicz I, Zych D, et al. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration. 1984;46:26–32.

    Article  CAS  PubMed  Google Scholar 

  111. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001;120:866–72.

    Article  CAS  PubMed  Google Scholar 

  112. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25: 783–8.

    Article  CAS  PubMed  Google Scholar 

  113. Emirgil C, Sobol BJ, Herbert WH, et al. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest. 1971;60:371–8.

    Article  CAS  PubMed  Google Scholar 

  114. Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest. 2010;138:1078–85.

    Article  PubMed  Google Scholar 

  115. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest. 2001;120:873–80.

    Article  CAS  PubMed  Google Scholar 

  116. Diaz-Guzman E, Farver C, Parambil J, et al. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med. 2008;29:549–63.

    Article  PubMed Central  PubMed  Google Scholar 

  117. Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128:1483–9.

    Article  PubMed  Google Scholar 

  118. Swigris JJ, Olson AL, Huie TJ, et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest. 2011;140:1261–6.

    Article  PubMed Central  PubMed  Google Scholar 

  119. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J. 2008;32:296–302.

    Article  CAS  PubMed  Google Scholar 

  120. Gluskowski J, Hawrylkiewicz I, Zych D, et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J. 1990;3:403–7.

    CAS  PubMed  Google Scholar 

  121. Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2013 Oct 31. doi: 10.1378/chest.13-1766.

  122. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:110–20.

    CAS  PubMed  Google Scholar 

  123. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest. 2009;135:1455–61.

    Article  PubMed Central  PubMed  Google Scholar 

  124. Soskel NT, Sharma OP. Pleural involvement in sarcoidosis. Curr Opin Pulm Med. 2000;6:455–68.

    Article  CAS  PubMed  Google Scholar 

  125. De Vuyst P, De Troyer A, Yernault JC. Bloody pleural effusion in a patient with sarcoidosis. Chest. 1979;76:607–9.

    Article  PubMed  Google Scholar 

  126. Aberg H, Bah M, Waters AW. Sarcoidosis: complicated by chylothorax. Minn Med. 1966;49:1065–70.

    CAS  PubMed  Google Scholar 

  127. Poe RH. Middle-lobe atelectasis due to sarcoidosis with pleural effusion. N Y State J Med. 1978;78:2095–7.

    CAS  PubMed  Google Scholar 

  128. Chusid EL, Siltzbach LE. Sarcoidosis of the pleura. Ann Intern Med. 1974;81:190–4.

    Article  CAS  PubMed  Google Scholar 

  129. Beekman JF, Zimmet SM, Chun BK, et al. Spectrum of pleural involvement in sarcoidosis. Arch Intern Med. 1976;136:323–30.

    Article  CAS  PubMed  Google Scholar 

  130. Huggins JT, Doelken P, Sahn SA, et al. Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest. 2006;129:1599–604.

    Article  PubMed  Google Scholar 

  131. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:119–27.

    CAS  PubMed  Google Scholar 

  132. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore). 1999;78: 65–111.

    Article  CAS  Google Scholar 

  133. Hours S, Nunes H, Kambouchner M, et al. Pulmonary cavitary sarcoidosis: clinico-radiologic characteristics and natural history of a rare form of sarcoidosis. Medicine (Baltimore). 2008;87:142–51.

    Article  Google Scholar 

  134. Jewkes J, Kay PH, Paneth M, et al. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax. 1983;38:572–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  135. Rockoff SD, Rohatgi PK. Unusual manifestations of thoracic sarcoidosis. AJR Am J Roentgenol. 1985;144:513–28.

    Article  CAS  PubMed  Google Scholar 

  136. Rubinstein I, Baum GL, Rosenthal T. Fungal infections complicating pulmonary sarcoidosis. J Infect Dis. 1985;152:1360.

    Article  CAS  PubMed  Google Scholar 

  137. Waldhorn RE, Tsou E, Kerwin DM. Invasive pulmonary aspergillosis associated with aspergilloma in sarcoidosis. South Med J. 1983;76:251–3.

    Article  CAS  PubMed  Google Scholar 

  138. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:696–709.

    Article  CAS  PubMed  Google Scholar 

  139. Jackson M, Flower CD, Shneerson JM. Treatment of symptomatic pulmonary aspergillomas with intracavitary instillation of amphotericin B through an indwelling catheter. Thorax. 1993;48:928–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  140. Kravitz JN, Steed LL, Judson MA. Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis. Med Mycol. 2011;49:198–201.

    Article  PubMed  Google Scholar 

  141. Dar MA, Ahmad M, Weinstein AJ, et al. Thoracic aspergillosis (Part I). Overview and aspergilloma. Cleve Clin Q. 1984;51:615–30.

    Article  CAS  PubMed  Google Scholar 

  142. Crawshaw AP, Wotton CJ, Yeates DG, et al. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax. 2011;66:447–8.

    Article  CAS  PubMed  Google Scholar 

  143. Perez RL, Duncan A, Hunter RL, et al. Elevated D dimer in the lungs and blood of patients with sarcoidosis. Chest. 1993;103:1100–6.

    Article  CAS  PubMed  Google Scholar 

  144. Turner GA, Lower EE, Corser BC, et al. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:61–4.

    CAS  PubMed  Google Scholar 

  145. Patterson KC, Huang F, Oldham JM, et al. Excessive daytime sleepiness and obstructive sleep apnea in patients with sarcoidosis. Chest. 2013;143:1562–8.

    Article  PubMed  Google Scholar 

  146. de Kleijn WP, De Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med. 2009;15(5):499–506.

    Article  PubMed  Google Scholar 

  147. Chowdhury FU, Sheerin F, Bradley KM, et al. Sarcoid-like reaction to malignancy on whole-body integrated (18)F-FDG PET/CT: prevalence and disease pattern. Clin Radiol. 2009;64:675–81.

    Article  CAS  PubMed  Google Scholar 

  148. Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101:2534–40.

    Article  PubMed  Google Scholar 

  149. Brincker H, Wilbek E. The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer. 1974;29:247–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  150. Askling J, Grunewald J, Eklund A, et al. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med. 1999;160:1668–72.

    Article  CAS  PubMed  Google Scholar 

  151. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  152. Swigris JJ, Olson AL, Huie TJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183:1524–30.

    Article  PubMed Central  PubMed  Google Scholar 

  153. Sekiguchi M, Yazaki Y, Isobe M, et al. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther. 1996;10:495–510.

    Article  CAS  PubMed  Google Scholar 

  154. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.

    Article  CAS  PubMed  Google Scholar 

  155. Nagai S, Shigematsu M, Hamada K, et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med. 1999;5:293–8.

    Article  CAS  PubMed  Google Scholar 

  156. Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:204–11.

    PubMed  Google Scholar 

  157. Chappell AG, Cheung WY, Hutchings HA. Sarcoidosis: a long-term follow up study. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:167–73.

    CAS  PubMed  Google Scholar 

  158. Mana J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases. Respiration. 1994;61:219–25.

    Article  CAS  PubMed  Google Scholar 

  159. Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99:307–15.

    Article  CAS  PubMed  Google Scholar 

  160. Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of the WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:56–64.

    CAS  PubMed  Google Scholar 

  161. Akira M, Kozuka T, Inoue Y, et al. Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest. 2005;127:185–91.

    Article  PubMed  Google Scholar 

  162. Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:154–8.

    CAS  PubMed  Google Scholar 

  163. Brauner MW, Lenoir S, Grenier P, et al. Pulmonary sarcoidosis: CT assessment of lesion reversibility. Radiology. 1992;182:349–54.

    CAS  PubMed  Google Scholar 

  164. Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med. 2010;31:501–18.

    Article  PubMed  Google Scholar 

  165. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1994;149:893–8.

    Article  CAS  PubMed  Google Scholar 

  166. Grunewald J, Eklund A. Lofgren’s syndrome: human leukocyte antigen strongly influence the disease course. Am J Respir Crit Care Med. 2009;179(4):307–12.

    Article  PubMed  Google Scholar 

  167. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997;111:623–31.

    Article  CAS  PubMed  Google Scholar 

  168. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J. 1995;8: 682–8.

    CAS  PubMed  Google Scholar 

  169. Erkkila S, Froseth B, Hellstrom PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis. 1988;5:106–10.

    CAS  PubMed  Google Scholar 

  170. Milman N, Graudal N, Grode G, et al. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med. 1994;236:285–90.

    Article  CAS  PubMed  Google Scholar 

  171. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis. 1993;10:56–61.

    CAS  PubMed  Google Scholar 

  172. du Bois RM, Greenhalgh PM, Southcott AM, et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J. 1999;13:1345–50.

    Article  PubMed  Google Scholar 

  173. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:198–204.

    PubMed  Google Scholar 

  174. Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci. 1986;465:702–12.

    Article  CAS  PubMed  Google Scholar 

  175. Sweiss N, Yeager H. Sarcoidosis requiring systemic treatment: why not a steroid-sparing regimen up-front? Sarcoidosis Vasc Diffuse Lung Dis. 2010;27: 3–4.

    CAS  PubMed  Google Scholar 

  176. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999;115:1158–65.

    Article  CAS  PubMed  Google Scholar 

  177. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005:CD001114.

    Google Scholar 

  178. Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a delphi consensus study. Respir Med. 2010;104(5): 717–23.

    Article  PubMed  Google Scholar 

  179. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA. 2002;287:1301–7.

    Article  CAS  PubMed  Google Scholar 

  180. Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125:997–1004.

    Article  PubMed  Google Scholar 

  181. Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis. 1993;147:1598–600.

    Article  CAS  PubMed  Google Scholar 

  182. Winterbauer RH, Kirtland SH, Corley DE. Treatment with corticosteroids. Clin Chest Med. 1997;18:843–51.

    Article  CAS  PubMed  Google Scholar 

  183. Goldstein DS, Williams MH. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids. Thorax. 1986;41:473–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  184. Siltzbach LE. Effects of cortisone in sarcoidosis; a study of thirteen patients. Am J Med. 1952;12: 139–60.

    Article  CAS  PubMed  Google Scholar 

  185. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:60–6.

    CAS  PubMed  Google Scholar 

  186. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 1996;51: 238–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  187. Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate versus azathioprine in second line therapy of sarcoidosis. Chest. 2013;144(3):805–12.

    Article  CAS  PubMed  Google Scholar 

  188. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 1999; 54:742–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  189. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155:846–51.

    Article  CAS  PubMed  Google Scholar 

  190. Webster GF, Razsi LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991;24:451–4.

    Article  CAS  PubMed  Google Scholar 

  191. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and other granulomatous disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19:545–61.

    Article  CAS  PubMed  Google Scholar 

  192. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38:1145–50.

    Article  CAS  PubMed  Google Scholar 

  193. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:43–8.

    PubMed  Google Scholar 

  194. Baltzan M, Mehta S, Kirkham TH, et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999;160:192–7.

    Article  CAS  PubMed  Google Scholar 

  195. Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731–40.

    Article  CAS  PubMed  Google Scholar 

  196. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A. 1997;94:8093–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  197. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.

    Article  CAS  PubMed  Google Scholar 

  198. Erckens RJ, Mostard RL, Wijnen PA, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  199. Kamphuis LS, Lam-Tse WK, Dik WA, et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med. 2011;184:1214–6.

    Article  PubMed  Google Scholar 

  200. Milman N, Graudal N, Loft A, et al. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6(4): 238–47.

    Article  CAS  PubMed  Google Scholar 

  201. Nathan SD. Lung transplantation: disease-specific considerations for referral. Chest. 2005;127: 1006–16.

    Article  PubMed  Google Scholar 

  202. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant. 2012;31:1073–86.

    Article  PubMed  Google Scholar 

  203. Shorr AF, Helman DL, Davies DB, et al. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest. 2004;125:990–6.

    Article  PubMed  Google Scholar 

  204. Nunley DR, Hattler B, Keenan RJ, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16: 93–100.

    CAS  PubMed  Google Scholar 

  205. Milman N, Burton C, Andersen CB, et al. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:222–8.

    PubMed  Google Scholar 

  206. Ionescu DN, Hunt JL, Lomago D, et al. Recurrent sarcoidosis in lung transplant allografts: granulomas are of recipient origin. Diagn Mol Pathol. 2005;14: 140–5.

    Article  PubMed  Google Scholar 

  207. Padilla ML, Schilero GJ, Teirstein AS. Sarcoidosis and transplantation. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:16–22.

    CAS  PubMed  Google Scholar 

  208. Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis. 1993;148:1373–7.

    Article  CAS  PubMed  Google Scholar 

  209. Heatly T, Sekela M, Berger R. Single lung transplantation involving a donor with documented pulmonary sarcoidosis. J Heart Lung Transplant. 1994;13:720–3.

    CAS  PubMed  Google Scholar 

  210. Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med. 2010;31:474–84.

    Article  PubMed  Google Scholar 

  211. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci. 1976;278:321–34.

    Article  CAS  PubMed  Google Scholar 

  212. Muther RS, McCarron DA, Bennett WM. Renal manifestations of sarcoidosis. Arch Intern Med. 1981;141:643–5.

    Article  CAS  PubMed  Google Scholar 

  213. Rizzato G, Fraioli P. Natural and corticosteroid-induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility. Sarcoidosis. 1990;7:89–92.

    CAS  PubMed  Google Scholar 

  214. Stoffels K, Overbergh L, Giulietti A, et al. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res. 2006;21:37–47.

    Article  CAS  PubMed  Google Scholar 

  215. Sweiss NJ, Lower EE, Korsten P, et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep. 2011;13: 265–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  216. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int. 1997;61:382–5.

    Article  CAS  PubMed  Google Scholar 

  217. FRAX. WHO Fracture Risk Assessment Tool, 2013.

    Google Scholar 

  218. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515–26.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Respiratory Institute, Cleveland Clinic, Desk A90, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Kristin B. Highland M.D., M.S.C.R. & Daniel A. Culver D.O.

Authors
  1. Kristin B. Highland M.D., M.S.C.R.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Culver D.O.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel A. Culver D.O. .

Editor information

Editors and Affiliations

  1. Harvard Medical School, Department of Medicine, Division of Rheumatology Brigham and Women’s Hospital, Boston, Massachusetts, USA

    Paul F. Dellaripa

  2. Division of Rheumatology, Autoimmune and Interstitial Lung Disease Program, Department of Medicine, National Jewish Health, Denver, Colorado, USA

    Aryeh Fischer

  3. Department of Internal Medicine, Division of Pulmonary/Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

    Kevin R. Flaherty

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Highland, K.B., Culver, D.A. (2014). Pulmonary Manifestations of Sarcoidosis. In: Dellaripa, P., Fischer, A., Flaherty, K. (eds) Pulmonary Manifestations of Rheumatic Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0770-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0770-0_9

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0769-4

  • Online ISBN: 978-1-4939-0770-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation